(Total Views: 378)
Posted On: 03/13/2018 5:19:47 PM
Post# of 72446
Hmmm.Let's see.PCYC bought for 21B for one drug expected to fetch $5B in 2020.Side effects and safety warnings quite intimidating too.
IPIX has 3 compounds addressing a minimum of 5 multi-multi billion $ markets and to date,no serious side effects.Psoriasis (oral treatment),BOM (Oral treatment),UP (Likely an oral treatment ultimately),Kevetrin for Ovarian Ca.(likely an oral treatment) and many many other possibilities of stand alone/combo therapies for a much wider range of cancers.
With little to no side effects,BP's not likely to be sued for injuries.(Huge advantage).But,NO,we're just not worth much compared to PCYC are we?
I figure at $5Bn/each of the 5 indications my math comes up with a minimum of $25Bn.But then we haven't explored the myriad of likely indications for each of the 3 platforms (P,B,K) not to mention the topical market(s) for B alone,have we.
But,ALAS,NO,we just aren't worth even the $21B that bought PCYC.
I guess we'll just have to accept $6/share and go home right?
GFY
Kelt
IPIX has 3 compounds addressing a minimum of 5 multi-multi billion $ markets and to date,no serious side effects.Psoriasis (oral treatment),BOM (Oral treatment),UP (Likely an oral treatment ultimately),Kevetrin for Ovarian Ca.(likely an oral treatment) and many many other possibilities of stand alone/combo therapies for a much wider range of cancers.
With little to no side effects,BP's not likely to be sued for injuries.(Huge advantage).But,NO,we're just not worth much compared to PCYC are we?
I figure at $5Bn/each of the 5 indications my math comes up with a minimum of $25Bn.But then we haven't explored the myriad of likely indications for each of the 3 platforms (P,B,K) not to mention the topical market(s) for B alone,have we.
But,ALAS,NO,we just aren't worth even the $21B that bought PCYC.
I guess we'll just have to accept $6/share and go home right?
GFY
Kelt
(6)
(0)
